Purpose: Checkpoint inhibitors are now a common treatment modality for metastatic cancer. In this manuscript, we describe the clinical features and management of autoimmune non-infectious uveitis induced by this class of drugs. Methods: Seven patients undergoing checkpoint inhibitor treatment for metastatic cancer from uveitis practices at three tertiary referral centers. Results: All seven patients developed various severities of ocular inflammatory disease while taking checkpoint inhibitors for metastatic disease. Conclusions: Checkpoint inhibitors may induce autoimmune uveitis. Ocular complaints should prompt an early evaluation by an ophthalmologist. [ABSTRACT FROM AUTHOR]